Novel hydrophilic analogs of 4,8-dihydrobenzodithiophene-4,8-diones as anticancer agents

ABSTRACT

The present invention discloses hydrophilic derivatives of 4,8-dihydrobenzodithiophene-4,8-diones, which are active as anticancer agents, along with pharmaceutical formulations containing the same.

CROSS-REFERENCE TO RELATED APPLICATION

This application claims the benefit of U.S. Provisional Application No. 60/613,225, filed 28 Sep. 2004.

FIELD OF THE INVENTION

The present invention concerns hydrophilic analogs of 4,8-dihydrobenzodithiophene-4,8-diones, which are active as anticancer agents, along with pharmaceutical formulations containing the same.

BACKGROUND OF THE INVENTION

In our prior studies, naphtho[2,3-b]thiophene4,9-diones (A), 4,8-dihydrobenzo[1,2-b:5,4-b′]dithiophene-4,8-diones(B) and, 4,8-dihydrobenzo[1,2-b:4,5-b′]dithiophene-4,8-diones(C) were identified as potential anticancer agents (U.S. Pat. Nos. 6,174,913 B1; 6,337,346B1, details of which are incorporated herein by reference]. Among these benzothiophene analogs, many compounds possessed very potent cytotoxic activity against human tumor cell lines. However, most of these compounds were quite lipophilic, and therefore, not optimal for in vivo and clinical studies.

SUMMARY OF THE INVENTION

The present invention was undertaken to synthesize novel hydrophilic analogs of dihydrobenzodithiophenediones and to evaluate their anticancer activity.

A first aspect of the present invention is a compound selected from the group consisting of compounds of formula (D) and compounds of formula (E):

wherein Y and Z independently are O, S, —NH—, or Se, and preferably Y and Z are S;

A₁ and A₂ independently are O, S, or NR₅, wherein R₅ is H or alkyl;

R₁, R₂, R₃ and R₄ independently are H, alkyl, —CR₅R₆—X—C(O)—(CH₂)_(n)COOH, —CR₅R₆—X—(CH₂)_(n)COOH, —CR₅R₆—X—(CH₂)_(n)NR₅R₆, —C(O)—NR₆—(CR₅R₆)_(n)COOH, —C(O)—NR₆—(CR₅R₆)_(n)NR₅R₆, —CR₅R₆—C(O)—(CH₂)_(n)COOH, —CR₅R₆—X—C(O)—(CH₂)_(n)NR₅R₆, —C(O)—(CR₅R₆)_(n)COOH, —C(O)—(CR₅R₆)_(n)NR₅R₆, —CR₅═N—(CH₂)_(n)COOH, —CR₅═N—(CH₂)_(n)NR₅R₆, —CR₅═NOH, or

wherein X is O, S, or NH; R₅ is defined as above; R₅ is H or alkyl; and n is 1-5; subject to the proviso that at least one of R₁, R₂, R₃ and R₄ is a radical other than hydrogen and alkyl; or a pharmaceutically acceptable salt thereof.

Preferably, R₂, R₃ and R₄ are H, and R₁ is —CR₅R₆—X—C(O)—(CH₂)_(n)COOH, —CR₅R₆—X—(CH₂)_(n)COOH, —CR₅R₆—X—(CH₂)_(n)NR₅R₆, —C(O)—NR₆—(CR₅R₆)_(n)COOH, or —C(O)—NR₆—(CR₅R₆)_(n)NR₅R₆, wherein X, R₅, R₆ and n are defined as above.

Preferably, A₁ and A₂ are O.

Preferably, X is O.

Preferably, R₅ and R₆ independently are H or methyl.

Preferably, R₂, R₃ and R₄ are H, and R₁ is —CR₅R₆—X—C(O)—(CH₂)_(n)COOH, wherein X, R₅, R₆ and n are defined as above.

Preferably, R₂, R₃ and R₄ are H, and R₁ is —CR₅R₆—X—(CH₂)_(n)COOH, wherein X, R₅, R₆ and n are defined as above.

Preferably, R₂, R₃ and R₄ are H, and R₁ is —CR₅R₆—X—(CH₂)_(n)NR₅R₆, wherein X, R₅, R₆ and n are defined as above.

Preferably, R₂, R₃ and R₄ are H, and R₁ is —C(O)—NR₆—(CR₅R₆)_(n)COOH, wherein X, R₅, R₆ and n are defined as above.

Preferably, R₂, R₃ and R₄ are H, and R₁ is —C(O)—NR₆—(CR₅R₆)_(n)NR₅R₆, wherein X, R₅, R₆ and n are defined as above.

Preferably, the compound of the present invention has the formula (D).

Preferably, the compound of the present invention has the formula (E).

Preferably, the compound of the present invention has the formula (D) is mono-[1-(4,8-dioxo-4,8-dihydrobenzo[1,2-b:5,4-b′]dithiophen-2-yl)-methyl]succinate (IIa-1), mono-[1-(4,8-dioxo-4,8-dihydrobenzo[1,2-b:5,4-b′]dithiophen-2-yl)ethyl]succinate (IIb-1), or mono-[1-(4,8-dioxo-4,8-dihydrobenzo[1,2-b:5,4-b′]dithiophen-2-yl)-ethyl]pentanedioate (IIb-2); and the compound of the present invention has the formula (E) is mono-[1-(4,8-dioxo-4,8-dihydroxybenzo[1,2-b;4,5-b′]dithiophen-2-yl)-ethyl]succinate (VII-1), mono-[1-(4,8-dioxo-4,8-dihydroxybenzo[1,2-b;4,5-b′]dithiophen-2-yl)-ethyl]pentanedioate (VII-2), or 4,8-dioxo-4,8-dihydrobenzo[1,2-b;4,5-b′]dithiophene-2-carboxylate-(2-dimethylamino-ethyl)-amide (XV-2).

A second aspect of the present invention is a composition comprising an effective anticancer amount of a compound of the formula (D) or (E) above, or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier.

A further aspect of the present invention is a method for treating a tumor, the method comprising administering to a subject in need of treatment a compound of the formula (D) or (E) above, or a pharmaceutically acceptable salt thereof, in an amount effective to treat said tumor.

A still further aspect of the present invention is the use of a compound of the formula (D) or (E) above, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for carrying out the method described above.

Preferably, said tumor is selected from the group consisting of non-small cell lung cancer, breast cancer, nasopharynx carcinoma, prostate cancer, colon cancer, hepatoma, ileocecal carcinoma, leukemia and central nervous system cancers, and more preferably said tumor is non-small cell lung cancer, breast cancer, nasopharynx carcinoma and prostate cancer.

DETAILED DESCRIPTION OF THE INVENTION

As part of a continuing search for potential anticancer drug candidates in the benzodithiophenedione series, novel hydrophilic analogs were synthesized and evaluated. A series of succinates (D, E) and amides (XV) derived from hydroxyalkyl-4,8-dihydrobenzo[1,2-b:5,4-b′]dithiophene-4,8-dione (I) and hydroxyalkyl-4,8-dihydrobenzo[1,2-b:4,5-b′]dithiophene-4,8-dione (VI) are worthy of further exploration for their anticancer activities.

The term “alkyl” as used herein, inidividually or as a portion of another substituent term such as “alkoxy”, refers to C1 to C4 alkyl, which may be linear or branched, and saturated or unsaturated. Preferably, the alkyl is saturated, and preferably the alkyl is linear.

The term “halogen” or “halo” as used herein refers to fluorine, chlorine, bromine, iodine, etc., or fluoro, chloro, bromo, iodo, etc., respectively.

Suitable methods for synthesizing the compounds of the present invention will be described in the following, and variations thereof will be apparent to those skilled in the art in given the Examples set forth below.

The key intermediates (I,VI) needed for the synthesis of target compounds were prepared according to our previously reported procedures [L. J. Huang, S. C. Kuo, C. Y. Perng, Y. H. Chao, T. S. Wu, A. T. Mcphail, A. Manger, H. Y. Cheng and K. H. Lee. Bioorg. Med. Chem. Lett 8, 2763-2768 (1998); Y. H. Chao, S. C. Kuo, C. H. Wu, C. Y. Lee, A. Manger, I. C. Sun, S. L. Morris-Natschke and K. H. Lee. J. Med. Chem. 41, 4658-4661 (1998); Y. H. Chao, S. C. Kuo, K. Ku, I. P. Chiu, C. H. Wu, A. Manger, H. K. Wang, and K. H. Lee. Bioorg. Med. Chem. 7, 1025-1031 (1999)].

As shown in Scheme 1. the mono-(4,8-dioxo-4,8-dihydrobenzo[1,2-b:5,4-b′]dithiophenyl-alkyl)alkanedioates (II) were obtained by treating the key intermediate I, hydroxyalkyl-4,8-dihydrobenzo[1,2-b:5,4-b′]dithiophene-4,8-diones, with anhydride in the presence of organic or inorganic base.

When the key intermediate I was reacted with a variety of haloalkanoates [X(CH₂)nCOOEt] in the presence of alkali, the corresponding alkoxyalkanoates (III) were obtained. Hydrolysis of compounding III with TFA or NaOH affords the corresponding acids (IV), which could be led to water soluble salts. Reaction of key intermediates I with a variety of haloalkylamines gave the corresponding alkoxyalkylamines (V), which could be treated with HCl, respectively, to afford their water soluble salts.

On the other hand, using the key intermediates VI, hydroxyalkyl-4,8-dihydrobenzo[1,2-b:4,5-b′]dithiophene-4,8-diones, as starting materials, following the similar procedures (Scheme 2) described above for the preparation of compounds II, IV, V, we successfully converted the key intermediates VI into hydrophilic target compounds VII, IX, X.

As shown in Scheme 3, the 4,8-dihydrobenzo[1,2-b:5,4b′]dithio-phene-4,8-dione-2-carboxylic acid XI was treated with amino acids in the presence of coupling agent to form the amides XII, which were then converted to the corresponding acids XIII. When XI was treated with NH₃, the corresponding ammonium salts (XI-NH₄) was obtained. On the other hand, compounds XI was allowed to react with SOCl₂ to afford the corresponding acid chloride, which was treated with a variety of aminoalkylamines to give corresponding amides (XVII) which could be treated with H₃PO₄ respectively to afford their water soluble salts (XVII-H₃PO₄).

When the 4,8-dihydrobenzo[1,2-b:4,5-b′]dithiophene-4.8-dione-2-carboxylic acids (XIV) were used as starting material following the similar procedures (Scheme 4) described above for the preparation of compounds XIII-Na, XI-NH₄ and XVII-H₃PO₄, we successfully converted the starting material XIV into target compounds XVI-Na and XIV-NH₄ and XVII-H₃PO₄.

The following Examples are provided to further illustrate the present invention, and should not be construed as limiting thereof. All melting points were determined on a Büchi MP-540 apparatus and are uncorrected. NMR spectra were obtained on a Varian Unity Inova-500 spectrometer in DMSO-d6, CD₃OD or CDCl₃. The chemical shift values are expressed in δ values (parts per million). The following abbreviations are used: s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, and br=broad, Mass spectra (MS) were measured with JEOL SX102A GC-MS instrument.

EXAMPLE 1 Mono-[1-(4,8-dioxo-4,8-dihydrobenzo[1,2-b:5,4-b′]dithiophen-2-yl)-methyl]succinate IIa-1

To a stirred solution of Ia (30 mg, 0.12 mmole) in CH₂Cl₂ (10 ml) were added succinic anhydride (120 mg, 1.2 mmole), Et₃N (25 mg, 1.23 mmole) and catalytic amount of DMAP (dimethyl aminopyridine). The reaction mixture was stirred at R.T. for 3 hr under N₂ and then washed with H₂O. The organic layer was extracted with aqueous NaHCO₃. To the aqueous layer was added CH₂Cl₂ and the pH was adjusted to 1 by 5N HCl. The organic layer was washed with H₂O and the volume was reduced. The solid precipitate was purified by reslurry with diethyl ether to yield yellow solid IIa-1 (13.2 mg, 30%).

¹H NMR (500 MHz, CDCl₃) δ 7.67 (d, J=5.0 Hz, 1H), 7.60 (dd, J=6.0, 5.0 Hz, 1H), 7.55 (d, J=6.0 Hz, 1H), 5.32 (s, 2H), 2.70 (s, 4H).

HRMS Calcd for C₁₅H₁₀O₆S₂: 349.9919, Found: 350.9995 (MH⁺, FAB).

mp=156° C. (decomp.)

EXAMPLE 2 Sodium mono-[1-(4,8-dioxo-4,8-dihydrobenzo[1,2-b:5,4-b′]dithiophen-2-yl)-methyl]succinate IIa-1-Na

To a stirred solution of IIa-1 (100.7 mg, 0.29 mmole) in EA was added sodium 2-ethylhexanoate (1.2˜1.5 eq.) in EA and stirred for overnight. The precipitate was filtered and washed with EA and then dried in vacuum. Yellow solid IIa-1-Na (100.6 mg, 93%) was obtained.

¹H NMR (500 MHz, CD₃OD) δ 7.96-7.93 (m, 1H), 7.63-7.60 (m, 2H), 5.36 (s, 2H), 2.63 (t, J=7.0 Hz, 2H), 2.48 (t, J=7.0 Hz, 2H).

mp=213° C. (decomp.)

EXAMPLE 3 Mono-[1-(4,8-dioxo-4,8-dihydrobenzo[1,2-b:5,4-b′]dithiophen-2-yl)-ethyl]succinate IIb-I

To a stirred solution of Ib (45 mg, 0.18 mmole) and CH₂Cl₂ (10 ml) were added succinic anhydride (150 mg, 1.5 mmole), Et₃N (150 mg, 1.54 mmole) and catalytic amount of DMAP (dimethyl aminopyridine). The reaction mixture was stirred at R.T. for 3 hr under N₂ and then washed with H₂O. The organic layer was extracted with aqueous NaHCO₃. To the aqueous layer was added CH₂Cl₂, and the pH was adjusted to 1 by 6N HCl. The separated CH₂Cl₂ layer was washed with H₂O and the volume was reduced. The solid precipitate was purified by reslurry with diethyl ether to yield yellow solid IIb-1 (11.7 mg, 17%).

¹H NMR (500 MHz, CDCl₃) δ 7.66 (d, J=5.0 Hz, 1H), 7.59 (d, J=5.0 Hz, 1H), 7.50 (s, 1H), 6.15 (q, J=6.0 Hz, 1H), 2.71-2.65 (m, 4H), 1.67 (d, J=6.0 Hz, 3H).

HRMS Calcd for C₁₆H₁₂O₆S₂: 364.0075, Found: 364.0074,

mp=132˜132.5° C.

EXAMPLE 4 Sodium mono-[1-(4,8-dioxo-4,8-dihydroxybenzo-[1,2-b;5,4-b′]dithiophen-2-yl)-ethyl]succinate IIb-1-Na

To a stirred solution of IIb-1 (100.8 mg, 0.28 mmole) in EA was added sodium 2-ethylhexanoate (1.2˜1.5 eq.) in EA and stirred for overnight. The precipitate was filtered and washed with EA and then dried in vacuum. Yellow solid IIb-1-Na (96.5 mg, 89%) was obtained.

¹H NMR (500 MHz, CD₃OD) δ 7.94 (d, J=5.0 Hz, 1H), 7.61 (d, J=5.0 Hz, 1H), 7.57 (s, 1H), 6.17 (q, J=6.5 Hz, 1H), 2.68-2.56 (m, 2H), 2.50-2.45 (m, 2H), 1.68 (d, J=6.5 Hz, 3H).

Mp=219° C. (decomp.)

EXAMPLE 5 Mono-[1-(4,8-dioxo-4,8-dihydroxybenzo[1,2-b;4,5-b′]dithiophen-2-yl)-ethyl]succinate VII-1

To a stirred solution of VI (50.0 mg, 0.19 mmole) and CH₂Cl₂ (3 ml) were added succinic anhydride (44.8 mg, 0.45 mmole), Et₃N (0.10 ml, 0.43 mmole) and DMAP (3.0 mg, 0.02 mmole). The reaction mixture was stirred at R.T. for 1.5 hr under N₂. After the addition of H₂O (1 ml) and 6N HCl (1 ml), the reaction mixture was extracted with CH₂Cl₂ (15 ml×3). The organic layer was dried over Na₂SO₄, filtered and concentrated to yield yellow-green solid VII-1 (62.0 mg, 90%).

¹H NMR (500 MHz, d₆-DMSO) δ 8.15 (d, J=4.5 Hz, 1H), 7.63 (s, 2H), 6.14 (q, J=6.5 Hz, 1H), 2.59-2.56 (m, 4H), 1.61 (d, J=6.5 Hz, 3H).

HRMS Calcd for C₁₆H₁₂O₆S₂: 364.0075, Found: 365.0156 (MH⁺, FAB).

Mp=163.5˜164.6 ° C.

EXAMPLE 6 Sodium mono-[1-(4,8-dioxo-4,8-dihydroxybenzo-[1,2-b;4,5-b′]dithiophen-2-yl)-ethyl]succinate VII-1-Na

To a stirred solution of VII-1 (200.0 mg, 0.55 mmole) in EA was added sodium 2-ethylhexanoate (1.2˜1.5 eq.) in EA and stirred for overnight. The precipitate was filtered and washed with EA and then dried in vacuum. Yellow-green solid VII-1-Na (191.0 mg, 90%) was obtained.

¹H NMR (500 MHz, CD3OD) δ 7.93 (d, J=5.0 Hz, 1H), 7.62 (d, J=5.0 Hz, 1H), 7.57 (s, 1H), 6.17 (q, J=6.5 Hz, 1H), 2.68-2.56 (m, 2H), 2.49-2.45 (m, 2H), 1.67 (d, J=6.5 Hz, 3H).

mp=240° C. (decomp.)

EXAMPLE 7 Mono-[1-(4,8-dioxo-4,8-dihydrobenzo[1,2-b:5,4-b′]dithiophen-2-yl)-methyl]pentanedioate IIa-2

To a stirred solution of Ia (54.0 mg, 0.22 mmole) and CH₂Cl₂ (3 ml) were added glutaric anhydride (49.7 mg, 0.44 mmole), DMAP (3.0 mg, 0.02 mmole) and Et₃N (0.06 ml, 0.40 mmole). The reaction mixture was stirred at R.T. for 3.5 hr under N₂. After the addition of H₂O (1 ml) and 2N HCl (3 ml), the reaction mixture was extracted with CH₂Cl₂ (15 ml×3). The organic layer was dried over Na₂SO₄, filtered and concentrated to get crude product. It was purified by column chromatography on silica gel eluting with CH₃OH: CH₂Cl₂ (1:40) to obtain compound IIa-2 (45.9 mg, 58%).

¹H NMR (500 MHz, CDCl₃) δ 7.67 (d, J=5.0 Hz, 1H), 7.61 (dd, J=5.5, 5.0 Hz, 1H), 7.55 (d, J=5.5 Hz, 1H), 5.29 (s, 2H), 2.48 (t, J=7.5 Hz, 2H), 2.44 (t, J=7.5 Hz, 2H), 2.02-1.95 (m, 2H).

HRMS Calcd for C₁₆H₁₂O₆S₂: 364.0075, Found: 364.0086.

mp=220° C. (decomp.)

EXAMPLE 8 Sodium mono-[1-(4,8-dioxo-4,8-dihydrobenzo[1,2-b:5,4-b′]dithiophen-2-yl)methyl]pentanedioate IIa-2-Na

To a stirred solution of IIa-2 (67.1 mg, 0.18 mmole) in EA was added sodium 2-ethylhexanoate (1.2˜1.5 eq.) in EA and stirred for overnight. The precipitate was filtered and washed with EA and then dried in vacuum. Yellowish brown solid IIa-2-Na (65.0 mg, 94%) was obtained.

¹H NMR (500 MHz, CD₃OD) δ 7.97-7.92 (m, 1H), 7.65-7.58 (m, 2H), 5.36 (s, 2H), 2.45 (t, J=7.8 Hz, 2H), 2.21 (t, J=7.8 Hz, 2H), 1.94-1.88 (m, 2H).

mp=203° C. (decomp.)

EXAMPLE 9 Mono-[1-(4,8-dioxo-4,8-dihydrobenzo[1,2-b:5,4-b′]dithiophen-2-yl)-ethyl]pentanedioate IIb-2

To a stirred solution of Ib (100.0 mg, 0.4 mmole) in CH₂Cl₂ (3 ml) were added glutaric anhydride (136.9 mg, 1.2 mmole), DMAP (5.0 mg, 0.04 mmole) and Et₃N (121 mg, 1.19 mmole). The reaction mixture was stirred at R.T. for overnight under N₂. After the addition of H₂O (1 ml) and 2N HCl (3 ml), the reaction mixture was extracted with CH₂Cl₂ (15 ml×3). The CH₂Cl₂ layer was dried over Na₂SO₄, filtered and concentrated to get crude product. It was purified by column chromatography on silica gel eluting with CH₃OH: CH₂Cl₂ (1:40) to obtain compound IIb-2 (128.0 mg, 88%).

¹H NMR (500 MHz, CDCl₃) δ 7.65 (d, J=5.0 Hz, 1H), 7.59 (d, J=5.0 Hz, 1H), 7.49 (s, 1H), 6.13 (q, J=6.5 Hz, 1H), 2.47-2.40 (m, 4H), 2.00-1.93 (m, 2H, 1.66 (d, J=6.5 Hz, 3H).

HRMS Calcd for C₁₇H₁₄O₆S₂: 378.0232, Found: 378.0229.

mp=100.5˜101.0° C.

EXAMPLE 10 Sodium mono-[1-(4,8-dioxo-4,8-dihydroxybenzo[1,2-b;5,4-b′]dithiophen-2-yl)-ethyl]pentanedioate IIb-2-Na

To a stirred solution of IIb-2 (83.0 mg, 0.22 mmole) in EA was added sodium 2-ethylhexanoate (1.2˜1.5 eq.) in EA and stirred for overnight. The precipitate was filtered and washed with EA and then dried in vacuum. Yellowish brown solid IIb-2-Na (83.1 mg, 94%) was obtained.

¹H NMR (500 MHz, CD₃OD) δ 7.94 (d, J=5.0 Hz, 1H), 7.62 (d, J=5.0 Hz, 1H), 7.57 (d, J=1.0 Hz, 1H), 6.18 (dd, J=6.5, 1.0 Hz, 1 1-), 2.43 (td, J=7.5, 2.5 Hz, 2H), 2.21 (t, J=7.5 Hz, 2H), 1.94-1.88 (m, 2H), 1.67 (d, J=6.5 Hz, 3H).

mp=228° C. (decomp.)

EXAMPLE 11 Mono-[1-(4,8-dioxo-4,8-dihydroxybenzo[1,2-b;4,5-b′]dithiophen-2-yl)-ethyl]pentanedioate VII-2

To a stirred solution of VI (50.0 mg, 0.19 mmole) in CH₂Cl₂ (3 ml) were added glutaric anhydride (45.2 mg, 0.4 mmole), DMAP (3.0 mg, 0.02 mmole) and Et₃N (0.05 ml, 0.4 mmole). The reaction mixture was stirred at R.T. for 15 hr under N₂. After the addition of H₂O-(1 ml) and 2N HCl (3 ml), the reaction mixture was extracted with CH₂Cl₂ (15 ml×3). The CH₂Cl₂ layer was dried over Na₂SO₄, filtered and concentrated to get crude product. It was purified by column chromatography on silica gel eluting with CH₃O: CH₂Cl₂ (1:50) to obtain compound VII-2 (32.7 mg, 46%).

¹H NMR (500 MHz, CDCl₃) δ 7.65 (d, J=5.0 Hz, 1H), 7.61 (d, J=5.0 Hz, 1H), 7.51 (s, 1H), 6.13 (q, J=6.5 Hz, 1H), 2.47-2.41 (m, 4H), 2.00-1.94 (m, 2H 1.66 (d, J=6.5 Hz, 3H).

HRMS Calcd for C₁₇H₁₄O₆S₂: 378.0232, Found: 379.0313 (MH⁺, FAB).

mp=141.6˜142.4° C.

EXAMPLE 12 Sodium mono-[1-(4,8-dioxo-4,8-dihydroxybenzo[1,2-b;4,5-b′]dithiophen-2-yl)-ethyl]pentanedioate VII-2-Na

To a stirred solution of VII-2 (109.4 mg, 0.29 mmole) in EA was added sodium 2-ethylhexanoate (1.2˜1.5 eq.) in EA and stirred for overnight. The s precipitate was filtered and washed with EA and then dried in vacuum. Yellow-green solid VII-2-Na (79.0 mg, 68%) was obtained.

¹H NMR (500 MHz, CD₃OD) δ 7.93 (d, J=5.0 Hz, 1H), 7.62 (d, J=5.0 Hz, 1H), 7.57 (s, 1H), 6.17 (q, J=6.5 Hz, 1H), 2.44 (td, J=7.5, 2.5 Hz, 2H), 2.22 (t, J=7.5 Hz, 2H), 1.95-1.88 (m, 2H), 1.68 (d, J=6.5 Hz, 3H).

mp=230° C. (decomp.)

EXAMPLE 13 t-Butyl 4,8-dioxo-4,8-dihydroxybenzo[1,2-b:5,4-b′]-dithiophen-2-yl-methoxy acetate IIIa-1

To a stirred solution of compound Ia (9.4 mg, 0.04 mmole) in toluene (2 ml) were added tetrabutylammonium hydrogen sulfate (4.0 mg, 0.01 mmole), 50% NaOH_((aq,)) (1 ml) and t-butyl bromoacetate (0.02 ml, 0.1 mmole). The mixture was stirred at R.T. for 2 hr. After the addition of H₂O, the reaction mixture was extracted with CH₂Cl₂ (15 ml×3). The CH₂Cl₂ layer was dried over Na₂SO₄, filtered and concentrated to get crude product. It was purified by plate liquid chromatography eluting with Ethyl acetate: Hexane (1:8) to obtain yellow solid IIIa-1 (2.7 mg, 20%).

¹H NMR (500 MHz, CDCl₃) δ 7.65 (d, J=5.0 Hz, 1H), 7.60 (dd, J=5.5, 5.0 Hz, 1H), 7.49 (d, J=5.5 Hz, 1H), 4.83 (s, 2H), 4.05 (s, 2H), 1.48 (s, 9H).

HRMS Calcd for C₁₇H₁₆O₅S₂: 364.0439, Found: 364.0425

mp=97.2˜97.8° C.

EXAMPLE 14 Ethyl 4,8-dioxo-4,8-dihydroxybenzo[1,2-b:5,4-b′]-dithiophen-2-yl-methoxy acetate IIIa

To a stirred solution of compound Ia (40 mg, 0.17 mmole) and toluene (10 ml) were added tetrabutylammonium hydrogen sulfate (20 mg, 0.06 mmole), 50% NaOH_((aq.)) (1 ml) and ethyl bromoacetate (0.1 ml, 0.9 mmole). The mixture was stirred at R.T. for 2 hr. After the addition of H₂O, the reaction mixture was extracted with CH₂Cl₂ (25 ml×3). The CH₂Cl₂ layer was dried over Na₂SO₄, filtered and concentrated to get crude product. It was purified by plate liquid chromatography eluting with CH₂Cl₂ to obtain yellow solid IIIa (18 mg, 33%).

¹H NMR (500 MHz, CDCl₃) δ 7.65 (d, J=5.0 Hz, 1H), 7.62-7.59 (m, ₁H), 7.51-7.49 (m, 1H), 4.85 (s, 2H), 4.24 (q, J=7.0 Hz, 2H), 4.16 (s, 2H), 1.29 (t, J=7.0 Hz, 3H).

HRMS Calcd for C₁₅H₁₂O₅S₂: 336.0126, Found: 336.0125.

mp=113.3˜113.5° C.

EXAMPLE 15 4,8-dioxo-4,8-dihydroxybenzo[1,2-b:5,4-b′]-dithiophen-2-yl-methoxy acetic acid IVa

To a stirred solution of compound IIIa-1 (2.7 mg, 0.007 mmole) and CH₂Cl₂ to (1 ml) was added trifluoroacetic acid (0.1 ml) and stirred at R.T. for 1.5 hr under N₂. After concentration, yellow solid IVa was obtained.

In a 25 mL flask were placed compound IIIa (15 mg, 0.05 mmole) and MeOH (10 m). LiOH (10 mg) in H₂O (8 ml) was then added and reaction mixture stirred at R.T. until hydrolysis completed. HOAc (˜0.4 ml) was added drop-wise to neutralize. MeOH was removed under vacuum and the residue was treated with aq. Na₂CO₃ and then extracted with CH₂Cl₂. The aqueous layer was acidified with dilute HCl solution until pH˜4 and the extracted with CH₂Cl₂. The CH₂Cl₂ layer was dried with Na₂SO₄, filtered and concentrated to obtain yellow solid IVa (12.5 mg, 91%).

¹H NMR (500 MHz, d₆-DMSO) δ 8.15 (d, J=5.0 Hz, 1H), 7.62 (dd, J=5.0, 4.5 Hz, 1H), 7.57 (d, J=4.5 Hz, 1H), 6.47 (s, 1H), 4.85 (s, 2H), 4.16 (s, 2H).

HRMS Calcd for C₁₃H₈O₅S₂: 307.9813, Found: 307.9847.

mp=218.0˜218.2° C.

EXAMPLE 16 Sodium 4,8-dioxo-4,8-dihydroxybenzo[1,2-b:5,4-b′]-dithiophen-2-yl-methoxy acetate IVa-Na

To a stirred solution of IVa (47.8 mg, 0.16 mmole) in EA was added sodium 2-ethylhexanoate (1.2˜1.5 eq.) in EA and stirred for overnight. The precipitate was filtered and washed with EA and then dried in vacuum. Yellow-green solid IVa -Na (35.4 mg, 70%).was obtained.

¹H NMR (500 MHz, CD₃OD) δ 7.93 (br, 1H), 7.62 (br, 1H), 7.54 (s, 1H), 4.88 (s, 2H), 3.97 (s, 2H).

mp=232.7° C. (decomp.)

EXAMPLE 17 t-Butyl 1-(4,8-dioxo-4,8-dihydroxybenzo[1,2-b:5,4-b′]-dithiophen-2-yl-ethoxy)-acetate IIIb-1

To a stirred solution of compound Ib (9.4 mg, 0.04 mmole) in toluene (2 ml) were added tetrabutylammonium hydrogen sulfate (4.0 mg, 0.01 mmole), 50% NaOH_((aq.)) (1 ml) and t-butyl bromoacetate (0.02 ml, 0.1 mmole). The mixture was stirred at R.T. for 2 hr. After the addition of H₂O, the reaction mixture was extracted with CH₂Cl₂ (15 ml×3), and the organic layer was dried over Na₂SO₄, filtered and concentrated to get crude product. It was purified by plate liquid chromatography eluting with ethyl acetate: Hexane (1:15) to obtain yellow solid IIIb-1 (6.9 mg, 51%).

¹H NMR (500 MHz, CDCl₃) δ 7.60 (d, J=5.0 Hz, 1H), 7.595 (d, J=5.0 Hz, 1H), 7.45 (s, 1H), 4.88 (q, J=6.5 Hz, 1H), 4.02, 3.91 (ABq, J=16.5 Hz, 2H), 1.62 (d, J=6.5 Hz, 3H), 1.46 (s, 9H).

HRMS Calcd for C₁₈H₁₈O₅S₂: 378.0596, Found, 378.0587

mp=108.0˜108.7° C.

EXAMPLE 18 Ethyl 1-(4,8-dioxo-4,8-dihydroxybenzo[1,2-b:5,4-b′]-dithiophen-2-yl-ethoxy)-acetate IIIb

To a stirred solution of compound Ib (100 mg, 0.4 mmole) in toluene (20 ml) were added tetrabutylammonium hydrogen sulfate (40 mg, 0.11 mmole), 50% NaOH_((aq.)) (1 ml) and ethyl bromoacetate (0.2 ml, 1.8 mmole). The mixture was stirred at R.T. for 2 hr. After the addition of H₂O, the reaction mixture was extracted with CH₂Cl₂ (20 ml×3). The CH₂Cl₂ layer was dried over Na₂SO₄, filtered and concentrated to get crude product. It was purified by plate liquid chromatography eluting with CH₂Cl₂ to obtain yellow solid. IIIb (65 mg, 48%).

¹H NMR (500 MHz, CDCl₃) δ 7.65 (d, J=5.0 Hz, ₁H), 7.60 (d, J=5.0 Hz, 1H), 7.46 (s, 1H), 4.89 (q, J=6.5 Hz, 1H), 4.21 (q, J=7.0 Hz, 2H), 4.12, 4.02 (ABq, J=16.5 Hz, 2H), 1.63 (d, J=6.5 Hz, 3H), 1.27 (t, J=7.0 Hz, 3H).

HRMS Calcd for C₁₆H₁₄O₅S₂: 350.0283, Found: 350.0271.

mp=122.7˜122.9° C.

EXAMPLE 19 1-(4,8-Dioxo-4,8-dihydroxybenzo[1,2-b;5,4-b′]-dithiophen-2-yl-ethoxy)-acetic acid IVb

In a 100 mL flask were placed compound IIIb (65 mg, 0.19 mmole) and MeOH (15 ml). LiOH (25.0 mg) in H₂O (12 ml) was then added and reaction mixture stirred at R.T. until hydrolysis completed. HOAc (˜1.4 ml) was added drop-wise to neutralize. MeOH was removed under vacuum and the residue was treated with aq. Na₂CO₃ and then extracted with CH₂Cl₂. The aqueous layer was acidified with dilute HCl solution until pH˜4 and the extracted with CH₂Cl₂. The CH₂Cl₂ layer was dried with Na₂SO₄, filtered and concentrated to obtain yellow solid IVb (54 mg, 90%).

¹H NMR (500 MHz, CD₃ OD) δ 7.95 (d, J=5.0 Hz, ₁H), 7.62 (d, J=5.0 Hz, 1H), 7.53 (s, 1H), 4.98 (q, J=6.5 Hz, 1H), 4.15, 4.09 (ABq, J=16.5 Hz, 2H), 1.61 (d, J=6.5 Hz, 3H).

HRMS Calcd for C₁₄H₁₀O₅S₂: 321.9970, Found: 321.9994.

mp=172.6˜173.0° C.

EXAMPLE 20 Sodium 1-(4,8-dioxo-4,8-dihydroxybenzo[1,2-b:5,4b′]-dithiophen-2-yl-ethoxy)-acetate IVb-Na

To a stirred solution of IVb (53.0 mg, 0.16 mmole) in EA was added sodium 2-ethylhexanoate (1.2˜1.5 eq.) in EA and stirred for overnight. The precipitate was filtered and washed with EA and then dried in vacuum. Yellow-green solid IVb-Na (33.1 mg, 58%) was obtained.

¹H NMR (500 MHz, D₂O) δ 7.87 (d, J=5.0 Hz, 1H), 7.32 (d, J=5.0 Hz, 1H), 7.27 (s, 1H), 4.98 (q, J=6.5 Hz, 1H), 4.02, 3.94 (ABq, J=16.0 Hz, 2H), 1.64 (d, J=6.5 Hz, 3H).

mp=243.8˜244.2° C.

EXAMPLE 21 t-Butyl 1-(4,8-dioxo-4,8-dihydroxybenzo[1,2-b:4,5-b′]-dithiophen-2-yl-ethoxy)acetate VII-1

To a stirred solution of compound VI (9.0 mg, 0.03 mmole) in toluene (2 ml) were added tetrabutylammonium hydrogen sulfate (4.0 mg, 0.01 mmole), 50% NaOH_((aq.)) (1 ml) and t-butyl bromoacetate (0.02 ml, 0.1 mmole). The mixture was stirred at R.T. for 2 hr. After the addition of H₂O, the reaction mixture was extracted with CH₂Cl₂ (15 ml×3), and the organic layer was dried over Na₂SO₄, filtered and concentrated to get crude product. It was purified by plate liquid chromatography eluting with ethyl acetate: Hexane (1:15) to obtain yellow oil VIII-1 (5.0 mg, 39%).

¹H NMR (500 MHz, CDCl₃) δ 7.65 (d, J=5.0 Hz, 1H), 7.61 (d, J=5.0 Hz, 1H), 7.46 (s, 1H), 4.87 (q, J=6.5 Hz, 1H), 4.01, 3.90 (ABq, J=16.5 Hz, 2H), 1.62 (d, J=6.5 Hz, 3H), 1.46 (s, 9H).

HRMS Calcd for C₁₈H₁₈O₅S₂: 378.0596, Found: 378.0573

EXAMPLE 22 Ethyl 1-(4,8-dioxo-4,8-dihydroxybenzo[1,2-b:4,5-b′]-dithiophen-2-yl-ethoxy)acetate VIII

To a stirred solution of compound VI (9.7 mg, 0.04 mmole) and toluene (2 ml) were added tetrabutylammonium hydrogen sulfate (4.0 mg, 0.01 mmole), 50% NaOH_((aq.)) (1 ml) and ethyl bromoacetate (0.1 mmole). The mixture was stirred at R.T. for 2 hr. After the addition of H₂O, the reaction mixture was extracted with CH₂Cl₂ (15 ml×3). The CH₂Cl₂ layer was dried over Na₂SO₄, filtered and concentrated to get crude product. It was purified by plate liquid chromatography eluting with CH₂Cl₂ to obtain yellow solid VIII (2.5 mg, 19%).

¹H NMR (500 MHz, CDCl₃) δ 7.65 (d, J=5.0 Hz, 1H), 7.61 (d, J=5.0 Hz, 1H), 7.47 (s, 1H), 4.89 (q, J=6.5 Hz, 1H), 4.21 (q, J=7.0 Hz, 2H), 4.12, 4.02 (ABq, J=16.5 Hz, 2H), 1.63 (d, J=6.5 Hz, 3H), 1.27 (t, J=7.0 Hz, 3H).

HRMS Calcd for C₁₆H₁₄O₅S₂: 350.0283, Found: 350.0284.

mp=106.2˜107.1° C.

EXAMPLE 23 1-(4,8-Dioxo-4,8-dihydroxybenzo[1,2-b:4,5-b′]-dithiophen-2-yl-ethoxy)-acetic acid IX

In a 25 mL flask were placed compound VIII (192.7 mg, 0.55 mmole) and MeOH (30 ml). LiOH (0.36 g) in H₂O (30 ml) was then added and reaction mixture stirred at R.T. until hydrolysis completed. HOAc (˜1.1 ml) was added drop-wise to neutralize. MeOH was removed under vacuum and the residue was treated with aq. Na₂CO₃ and then extracted with EA. The aqueous layer was acidified with dilute HCl solution until pH˜4 and the extracted with EA. The EA layer was dried with Na₂SO₄, filtered and concentrated to obtain yellow solid IX (160.0 mg, 90%).

¹H NMR (500 MHz, CD₃OD) δ 7.90 (d, J=5.0 Hz, 1H), 7.60 (d, J=5.0 Hz, 1H), 7.51 (s, 1H), 4.96 (q, J=6.5 Hz, 1H), 4.15, 4.09 (ABq, J=16.5 Hz, 2H), 1.61 (d, J=6.5 Hz, 3H).

HRMS Calcd for C₁₄H₁₀O₅S₂: 321.9970, Found: 323.0054 (MH⁺, FAB).

mp=172.1˜172.8 ° C.

EXAMPLE 24 Sodium 1-(4,8-dioxo-4,8-dihydroxybenzo[1,2-b:4,5-b′]-dithiophen-2-yl-ethoxy)-acetate IX-Na

To a stirred solution of IX (85.0 mg, 0.28 mmole) in EA was added sodium 2-ethylhexanoate (1.2˜1.5 eq.) in EA and stirred for overnight, The precipitate was filtered and washed with EA and then dried in vacuum. Yellow solid IX-Na (83.0 mg, 92%) was obtained.

¹H NMR (500 MHz, CD₃OD) δ 7.92 (d, J=5.0 Hz, 1H), 7.62 (d, J=5.0 Hz, 1H), 7.52 (s, 1H), 4.96 (q, J=6.5 Hz, 1H), 3.92, 3.83 (ABq, J=15.5 Hz, 2H), 1.60 (d, J=6.5 Hz, 3H).

mp=223° C. (decomp.)

EXAMPLE 25 2-[1-(2-Pyrrol-1-yl-propoxy)-ethylbenzo[1,2-b:4,5-b′]dithiophen-4,8-dione X

To a stirred solution of compound VI (10.5 mg, 0.04 mmole) in toluene (2 ml) were added tetrabutylammonium hydrogen sulfate (4.0 mg, 0.01 mmole), 50% NaOH_((aq.)) (2 ml) and 1-(3-bromopropyl)pyrrole (0.1 mmole). The mixture was stirred at R.T. for 3 hr. After the addition of H₂O, the reaction mixture was extracted with CH₂Cl₂ (15 ml×3). The CH₂Cl₂ layer was dried over Na₂SO₄, filtered and concentrated to get crude product. It was purified by plate liquid chromatography eluting with CH₂Cl₂ to obtain yellow oil X (5.0 mg, 34%).

¹H NMR (500 MHz, CDCl₃) δ 7.65 (d, J=5.0 Hz, 1H), 7.61 (d, J=5.0 Hz, 1H), 7.41 (s, 1H), 6.61 (s, 2H), 6.10 (s, 2H), 4.64 (q, J=6.5 Hz; 1H), 4.06-3.94 (m, 2H), 3.38 (t, J=5.5 Hz, 2H), 2.04-1.99 (m, 2H), 1.56 (d, J=6.5 Hz, 3H).

HRMS Calcd for C₁₉H₁₇NO₃S₂: 371.0650, Found: 371.0663

EXAMPLE 26 4,8-dioxo-4,8-dihydrobenzo[1,2-b;5,4-b′]dithiophene-2-carboxylate-(2-dimethylamino-ethyl)-amide XVII

Compound XI (60 mg, 0.23 mmole) in SOCl₂ (5 ml) was heated to reflux for 2 hrs. The excess SOCl₂ was removed to yield crude acid chloride. The acid chloride obtained was used directly without purification. It was diluted with CH₂Cl₂ (4 ml) and added to the N,N-dimethylethylenediamine (1.5 ml), Et₃N (2 ml) and CH₂Cl₂ (4 ml) mixture and stirred at R.T. for 1.5˜2 hrs. Water was added and the reaction mixture extracted with CH₂Cl₂, The CH₂Cl₂ layer was concentrated and crude product was purified through column using MeOH: CH₂Cl₂=1:8 as the eluent. Yellow solid XVII (50.0 mg, 67%) was obtained.

¹H NMR (500 MHz, CD₃OD) δ 8.14 (d, J=2.0 Hz, 1H), 7.97˜8.00 (m, 1H), 7.65 (d, J=5.0 Hz, 1H), 3.54 (t, J=6.5 Hz, 2H), 2.59 (t, J=6.5 Hz, 2H), 2.33 (s, 6H).

HRMS Calcd for C₁₅H₁₄N₂O₃S₂: 334.0446, Found: 334.0435

mp=197.5˜198.0° C.

EXAMPLE 27 4,8dioxo-4,8-dihydrobenzo[1,2-b;5,4-b′]dithiophene-2-carboxylate-(2-dimethyl-aminoethyl)-amide phosphoric acid salt XVII-H₃PO₄

To a stirred solution of XVII (31 mg, 0,093 mmole) in THF was added 85% H₃PO₄ (1.2˜1.5 eq.) and stirred for overnight. The precipitate was filtered and washed with THF and then dried in vacuum. Yellow solid XVII-H₃PO₄ (39 mg, 97%) was obtained.

¹H NMR (500 MHz, D₂O) δ 8.16 (s, 1H), 8.02 (d, J=5.0 Hz, 1H), 7.66 (d, J=5.0 Hz, 1H), 3.78 (t, J=6.0 Hz, 2H), 3.37 (t, J=6.0 Hz, 2H), 2.97 (s, 6H).

mp=222.5° C. (decomp.)

EXAMPLE 28 (a) Ammonium 4,8-dioxo-4,8-dihydrobenzo-[1,2-b:5,4-b′]dithiophene-2-carboxylate XI-NH,

Aqueous ammonium hydroxide (29.5%) was added to the solution of compound XI (230 mg, 0.87 mmole) in IPA (40 mL) until basic. After stirring for a while, all the volatile solvent was removed to yield green-yellow solid XI-NH₄ (200 mg, 82%)

¹H NMR (500 MHz, CD₃OD) δ 7.94 (d, J=5.0 Hz, 1H), 7.91 (s, 1H), 7.62 (d, J=5.0 Hz, 1H).

mp=257˜259° C.

(b) Sodium 4,8-dioxo-4,8-dihydrobenzo-[1,2-b:5,4-b′]dithiophene-2 carboxylate XI-Na

To a stirred solution of XI (206.7 mg, 0.83 mmole) in EA was added sodium 2-ethylhexanoate (1.2˜1.5 eq.) in EA and stirred for overnight. The precipitate was filtered and washed with EA and then dried in vacuum. Yellowish brown solid XI-Na (202.5 mg, 90%) was obtained.

1H NMR (500 MHz, CD₃OD) δ 7.93 (dd, J=5.0, 2.0 Hz, 1H), 7.90 (d, J=2.0 Hz, 1H), 7.62 (d, J=5.0 Hz, 1H).

mp=>275° C. (decomp.)

EXAMPLE 29 (2S)-[(4,8-Dioxo-4,8-dihydroxybenzo[1,2-b:5,4-b′]dithiophen-2-carbonyl)-amino]-phenyl-acetic acid methyl ester XII-1

To a stirred solution of XI (40.0 mg, 0.15 mmole) and THF (2 ml) were added (S)-phenyl glycine methyl ester HCl salt (31 mg, 0.15 mmole), EDC (30.5 mg, 0.16 mmole), HOBt (21 mg, 0.15 mmole) and 4-ethylmorpholine (0.02 ml, 0.15 mmole). After stirring at R.T. for overnight under N₂, the solvent was removed under reduced pressure. CH₂Cl₂ (3 ml) was added to the residue and the insoluble solid was removed. The CH₂Cl₂ layer was then washed with saturated NaHCO₃ solution, 1M KHSO₄, saturated NaHCO3 solution and H₂O. The organic layer was dried over Na₂SO₄, filtered and concentrated to get crude product. It was purified by column chromatography on silica gel eluting with EA: Hexanes (1:3) to obtain yellow solid XII-1 (21.1 mg, 34%).

¹H NMR (500 MHz, CDCl₃) δ 7.95 (s, 1H), 7.71 (d, J=4.3 Hz, 1H), 7.64 (d, J=4.3 Hz, 1H), 7.41-7.30 (m, 5H), 7.16 (d, J=6.5 Hz, 1H), 5.71 (d, J=6.5 Hz, 1H), 3.78 (s, 3H).

HRMS Calcd for C₂₀H₁₃NO₅S₂: 411,0235, Found: 411.0229

mp=211.1˜211.9° C.

EXAMPLE 30 [(4,8-Dioxo-4,8-dihydroxybenzo[1,2-b;5,4-b′]dithiophen-2-carbonyl)-amino]-acetic acid isopropyl ester XII-2

To a stirred solution of XI (52.6 mg, 0.20 mmole) and THF (2 ml) were added isopropyl glycinate HCl salt (30.4 mg, 0.21 mmole), EDC (40.1 mg, 0.21 mmole), HOBt (27.0 mg, 0.21 mmole) and 4-ethylmorpholine (0.03 ml, 0.21 mmole). After stirring at R.T. for overnight under N₂, the solvent was removed under reduced pressure. CH₂Cl₂ (3 ml) was added to the residue and the insoluble solid was removed. The CH₂Cl₂ layer was then washed with saturated NaHCO₃ solution, 1M KHSO₄, saturated NaHCO₃ solution and H₂O. The organic layer was dried over Na₂SO₄, filtered and concentrated to get crude product. It was purified by column chromatography on silica gel eluting with EA: CH₂Cl₂ (1:20) to obtain yellow solid XII-2 (31.7 mg, 44%).

¹H NMR (500 MHz, CDCl₃) δ 7.94 (s, 1H), 7.71 (d, J=4.5 Hz, 1H), 7.63 (d, J=4.5 Hz, 1H), 6.73 (s, 1H), 5.12 (septet, J=6.5 Hz, 1H), 4.18 (d, J=4.5 Hz, 2H), 1.29 (d, J=6.5 Hz, 6H).

HRMS Calcd for C₁₆H₁₃NO₅S₂: 363.0235, Found: 363.0226

mp=240.2˜240.5° C.

EXAMPLE 31 (2S)-[(4,8-Dioxo-4,8-dihydroxybenzo[1,2-b;4,5b′]dithiophen-2-carbonyl)-amin o]-propionic acid methyl ester XII

To a stirred solution of XI (40.0 mg, 0.15 mmole) and THF (2 ml) were added (S)-alanine methyl ester HCl salt (21 mg, 0.15 mmole), EDC (30.5 mg, 0.16 mmole), HOBt (21 mg, 0.15 mmole) and 4-ethylmorpholine (0.02 ml, 0.15 mmole). After stirring at R.T. for overnight under N₂, the solvent was removed under reduced pressure. CH₂Cl₂ (3 ml) was added to the residue and the insoluble solid was removed. The CH₂Cl₂ layer was then washed with saturated NaHCO₃ solution, 1M KHSO₄, saturated NaHCO₃ solution and H₂O. The organic layer was dried over Na₂SO₄, filtered and concentrated to get crude product. It was purified by column chromatography on silica gel eluting with EA: Hexanes (1:2) to obtain yellow solid XII (27.5 mg, 52%).

¹H NMR (500 MHz, CDCl₃) δ 7.92 (s, 1H), 7.72 (d, J=5.0 Hz, 1H), 7.64 (d, J=5.0 Hz, 1H), 6.75 (d, J=6.5 Hz, 1H), 4.78-4.72 (m, 1H), 3.80 (s, 3H), 1.54 (d, J=7.0 Hz, 3H).

HRMS Calcd for C₁₅H₁₁NO₅S₂: 349.0079, Found: 349.0061.

mp=188.1˜188.6° C.

EXAMPLE 32 (L)-2-{(4,8-Dioxo-4,8-dihydrobenzo-[1,2-b;5,4-b′]dithiophene-2-carbonyl)-amino}-propionic acid XIII

In a 25 mL flask were placed compound XII (130 mg, 0.37 mmole) and MeOH (37 ml), LiOH (322.5 mg) in H₂O (30 ml) was then added and reaction mixture stirred at R.T. until hydrolysis completed. HOAc (˜1.0 ml) was added dropwise to neutralize. MeOH was removed under vacuum and the residue was treated with aq. Na₂CO₃ and then extracted with EA. The aqueous layer was acidified with dilute HCl solution until pH˜4 and the extracted with EA. The EA layer was dried with Na₂SO₄, filtered and concentrated to obtain yellow solid XIII (120 mg, 96%).

¹H NMR (500 MHz, CD₃OD) δ 8.25 (s, 1H), 8.00 (d, J=5.0 Hz, 1H), 7.66 (d, J=5.0 Hz, 1H), 4.58 (q, J=7.5 Hz, 1H), 1.53 (d, J=7.5 Hz, 3H).

HRMS Calcd for C₁₄H₉NO₅S₂: 334.9922, Found; 334.9931

mp=239° C. (decomp.)

EXAMPLE 33 Sodium (L)-2-{(4,8-dioxo-4,8-dihydrobenzo-[1,2-b;5,4-b′]dithiophene-2-carbonyl)-amino}-propionate XIII-Na

To a stirred solution of XIII (50.5 mg, 0.15 mmole) in EA was added sodium 2-ethylhexanoate (1.2˜1.5 eq.) in EA and stirred for overnight. The precipitate was filtered and washed with EA and then dried in vacuum. Yellow solid XIII-Na (27.8 mg, 52%) was obtained.

¹H NMR (50 MHz, D₂O) δ 7.93 (br, 1H), 7.80 (d, J=5.0 Hz, 1H), 7.44 (d, J=5.0 Hz, 1H), 4.31 (q, J=6.5 Hz, 1H), 1.50 (d, J=6.5 Hz, 3H).

mp=200.5° C. (decomp.)

EXAMPLE 34 Ammonium 4,8-dioxo-4,8-dihydrobenzo-[1,2-b;4,5-b′]dithiophene-2-carboxylate XIV-NH₄

Compound XIV (140 mg, 0.53 mmole) was added in IPA (20 mL) and stirred at 60° C. for 30 min. The solid that was not soluble in IPA was filtered. Aqueous ammonium hydroxide (29.5%) was added to the filtrate until basic. After stirring for a while, the solvent was evaporated to yield green-yellow solid XIV-NH₄ (68.5 mg, 46%)

¹H NMR (500 MHz, CD₃OD) δ 7.97 (s, 1H), 7.94 (d, J=5.0 Hz, 1H), 7.64 (d, J=5.0 Hz, 1H).

mp>300 ° C.

EXAMPLE 35 [(4,8-Dioxo-4,8-dihydroxybenzo[1,2-b;4,5-b′]dithiophen-2-carbonyl)-amino]-acetic acid isopropyl ester XV

To a stirred solution of XIV (244.6 mg, 0.90 mmole) and THF (8 ml) were added isopropyl glycinate HCl salt (140.0 mg, 0.92 mmole), EDC (190.0 mg, 0.99 mmole), HOBt (125.0 mg, 0.93 mmole) and 4-ethylmorpholine (0.12 ml, 0.80 mmole). After stirring at R.T. for overnight under N₂, the solvent was removed under reduced pressure. CH₂Cl₂ (12 ml) was added to the residue and the insoluble solid was removed. The CH₂Cl₂ layer was then washed with saturated NaHCO₃ solution, 1M KHSO₄, saturated NaHCO3 solution and H₂O. The organic layer was dried over Na₂SO₄, filtered and concentrated to get crude product. It was purified by column chromatography on silica gel eluting with EA: CH₂Cl₂ (1:30) to obtain yellow solid XV (75.1 mg, 21%).

¹H NMR (500 MHz, CDCl₃) δ 7.95 (s, 1H), 7.70 (d, J=5.0 Hz, 1H), 7.65 (d, J=5.0 Hz, 1H), 6.73 (t, J=4.5 Hz, 1H), 5.12 (septet, J=6.5 Hz, 1H), 4.18 (d, J=4.5 Hz, 2H), 1.29 (d, J=6.5 Hz, 6H).

HRMS Calcd for C₁₆H₁₃NO₅S₂: 363.0235, Found: 363.0228

mp=231.8˜233.0° C.

EXAMPLE 36 Methyl (L)-2-{(4,8-Dioxo-4,8-dihydrobenzo-[1,2-b:4,5-b′]dithiophene-2-carbonyl)-amino}propionate XV-1

To a stirred solution of XIV (79.8 mg, 0.30 mmole) in THF (10 ml) were added (S)-alanine methyl ester HCl salt (42.0 mg, 0.30 mmole), EDC (61.0 mg, 0.32 mmole), HOBt (42 mg, 0.30 mmole) and 4-ethylmorpholine (0.04 ml, 0.30 mmole). After stirring at R.T. for overnight under N₂, the solvent was removed under reduced pressure. CH₂Cl₂ (3 ml) was added to the residue and the insoluble solid was removed. The CH₂Cl₂ layer was then washed with saturated NaHCO₃ solution, 1M KHSO₄, saturated NaHCO₃ solution and H₂O. The organic layer was dried over Na₂SO₄, filtered and concentrated to get crude product. It was purified by column chromatography on silica gel eluting with EA: Hexanes (1:2) to obtain yellow solid XV-1 (38.1 mg, 36%).

¹H NMR (500 MHz, CDCl₃) δ 7.94 (s, 1H), 7.71 (d, J=5.0 Hz, 1H), 7.65 (d, J=5.0 Hz, 1H), 6.80 (d, J=6.5 Hz, 1H), 4.75 (qd, J=7.5, 6.5 Hz, 1H), 3.80 (s, 3H), 1.53 (d, J=7.5 Hz, 3H).

HRMS Calcd for C₁₅H₁₁NO₅S₂: 349.0079, Found: 350.0159 (MH⁺, FAB).

mp=216.8˜217.7 ° C.

EXAMPLE 37 (L)-2-{(4,8-Dioxo-4,8-dihydrobenzo-[1,2-b;4,5-b′]dithiophene-2-carbonyl)-amino}-propionic acid XVI

In a 25 mL flask were placed compound XV-1 (17.6 mg, 0.05 mmole) and MeOH (5 ml). LiOH (45.0 mg) in H₂O (4 ml) was then added and reaction mixture stirred at R.T. until hydrolysis completed. HOAc (˜0.14 ml) was added drop-wise to neutralize. MeOH was removed under vacuum and the residue was treated with aq. Na₂CO₃ and then extracted with EA. The aqueous layer was acidified with dilute HCl solution until pH˜4 and the extracted with EA. The EA layer was dried with Na₂SO₄, filtered and concentrated to obtain yellow solid XVI (16.8 mg, 99%).

¹H NMR (500 MHz, CDCl₃) δ 7.96 (s, 1H), 7.62 (d, J=5.0 Hz, 1H), 7.47 (d, J=5.0 Hz, 1H), 4.47 (q, J=7.5 Hz, 1H), 1.36 (d, J=7.5 Hz, 3H).

mp=227.4˜228.3° C.

EXAMPLE 38 Sodium (L-2-{(4,8-dioxo-4,8-dihydrobenzo-[1,2-b;4,5-b′]dithiophene-2-carbonyl)-amino}-propionate XVI-Na

To a stirred solution of XVI (73.8 mg, 0.22 mmole) in EA was added sodium 2-ethylhexanoate (1.2˜1.5 eq.) in EA and stirred for overnight. The precipitate was filtered and washed with EA and then dried in vacuum. Yellow-green solid XVI-Na (47.5 mg, 60% ) was obtained.

¹H NMR (500 MHz, CD₃OD) δ 8.25 (s, 1H), 7.96 (d, J=5.0 Hz, 1H), 7.65 (d, J=5.0 Hz, 1H), 4.43 (q, J=7.0 Hz, 1H), 1.48 (d, J=7.0 Hz, 3H).

mp>275° C.

EXAMPLE 39 4,8-dioxo-4,8-dihydrobenzo[1,2-b;4,5-b′]dithiophene-2-carboxylate-(2-dimethylamino-ethyl)-amide XV-2

Compound XIV (0.6086 g, 2.0 mmole), SOCl₂ (50 ml) along with a small amount of NaCl was heated to reflux for 2 hrs. The excess SOCl₂ was removed and CH₂Cl₂ was added to the residue. NaCl was filtered and the filtrate was concentrated to yield crude acid chloride (0.5453 g). The acid chloride obtained was used directly without purification. It was diluted with CH₂Cl₂ (40 ml) and added to the N,N-dimethylethylenediamine (16 ml), Et₃N (20 ml) and CH₂Cl₂ (40 ml) mixture and stirred at R.T. for 12 hrs. Water was added and the reaction mixture extracted with CH₂Cl2 The CH₂Cl₂ layer was concentrated and crude product was purified through column using MeOH: CH₂Cl₂=1:10 as the eluent. Yellow solid XV-2 (255.2 mg, 33%) was obtained.

¹H NMR (500 MHz, CD₃OD) δ 8.13 (s, 1H), 7.97 (d, J=5.0 Hz, 1H), 7.65 (d, J=5.0 Hz, 1H), 3.55 (t, J=6.5 Hz, 2H), 2.65 (t, J=6.5 Hz, 2H), 2.37 (s, 6H).

HRMS Calcd for C₁₅H₁₄N₂O₃S₂: 334.0446, Found: 334.0641.

mp=235.5˜236.2° C.

EXAMPLE 40 4,8-dioxo-4,8-dihydrobenzo[1,2-b;4,5-b′]dithiophene-2-carboxylate-(2-dimethyl-aminoethyl)-amide phosphoric acid salt XV-2-H₃PO₄

To a stirred solution of XV-2 (100 mg, 0.30 mmole) in THF was added 85% H₃PO₄ (1.2˜1.5 eq.) and stirred for overnight. The precipitate was filtered and washed with THF and then dried in vacuum. Yellow solid XV-2-H₃PO₄ (120 mg, 93%) was obtained.

hu 1H NMR (500 MHz, D₂O) δ 8.02 (br, 1H), 7.82 (br, 1H), 7.54 (br, 1H), 3.88 (br, 2H), 3.52 (br, 2H), 3.08 (br, 6H).

mp=233° C. (decomp.)

Cytotoxicity Assays Method A (HUVEC, MCF-7, HT-29, Hep 3B and NCl-H460) [S. A. Ahmed, R. M. Gogal Jr., and J. E. Walsh, Journal of Immunological Methods 170: 211-224, (1994): M. R. Boyd, Status of the NCl preclinical antitumor drug discovery screen. (Published by J. B. Lippincoft Company, Philadelphia, Pa. 19105, USA) Principles & Practices of Oncology Updates 3# 10: 1-12, (1989); M. R. Boyd, et al. Data display and analysis strategies for the NCl disease-oriented in vitro antitumor drug screen. In: Cytotoxic anti-cancer drugs: models and concepts for drug discovery and development. Boston: Kluwer Academic, Pages; 11-34, (1992)]

1. Materials and Equipment

(1) Test Substance and Dosing Pattern

The test compounds were dissolved in 100% DMSO and then diluted with sterile distilled water to obtain initial working solutions of 20000, 2000, 200, 20 and 2 μM in 80% DMSO. A 200 fold dilution was further made in culture media to generate final assay concentrations of 100, 10, 1, 0.1 and 0.01 μM in 0.4% DMSO.

(2) Cell Culture Media Cell Lines Culture Medium HUVEC Endothelial Cell Growth Medium, 90%; Fetal Bovine Serum, 10% MCF-7 Minimum Essential Medium, 90%; Fetal Bovine Serum, 10% HT-29 McCoy's 5A medium, 90%; Fetal Bovine Serum, 10% Hep 3B Minimum Essential Medium, 90%; Fetal Bovine Serum, 10% NCI-H460 RPMI 1640, 90%; Fetal Bovine Serum, 10%

All of media were supplemented with 1% Antibiotic-Antimycotic.

(3) Cell Lines Cell Name Source Type of Cell Line HUVEC ATCC Human umbilical vein endothelial cells CRL-1730 MCF-7 ATCC HTB-22 Breast adenocarcinoma, pleural effusion, human HT-29 ATCC HTB-38 Adenocarcinoma, colon, moderately well-differentiated grade II, human Hep 3B ATCC HB-8064 Hepatocellular carcinoma, liver, human NCI-H460 ATCC HTB-177 Large cell carcinoma, lung, human

All of the human tumor cell lines and HUVEC were obtained from American Type Culture Collection (ATCC). The cells were all incubated at 37° C. with 5 % CO₂ in air atmosphere.

(4) Chemicals

AlamarBlue (Biosource, USA), Antibiotics-Antimycotic (GIBCO BRL, USA), Dimethylsulfoxide (Merck, Germany), Endothelial Cell Growth Medium (CELL APPLICATIONS, INC., USA), Fetal Bovine Serum (HyClone, USA), McCoy's 5A Medium (GIBCO BRL. USA), Minimum Essential medium (GIBCO BRL, USA), Mitomycin (Kyowa, Japan) and RPMI 1640 (HyClone, USA).

(5) Equipment

CO₂ Incubator (Forma Scientific Inc., USA), Centrifuge 5810R (Eppendorf, Germany), Hemacytometer (Hausser Scientific Horsham, USA), Inverted Microscope CK-40 (Olympus, Japan), System Microscope E-400 (Nikon, Japan), Spectrafluor Plus (Tecan, Austria) and Vertical Laminar Flow (Tsao Hsin, R. O. C.).

2. Methods

(1) Evaluation of Anti-Proliferative Activity for Test Substances

Aliquots of 100 μl of cell suspension (about 1.5-3.0×10³/well) were placed in 96-well microtiter plates in an atmosphere of 5% CO₂ at 37° C. After 24 hours, 100 μl of growth medium and 1 μl of test solution or vehicle (80% DMSO) were added respectively per well in duplicate for an additional 72-hour incubation. Thus, the final concentration of DMSO was 0.4%. The test compounds, IIa-1, IIb-1 and VII-1 were evaluated at concentrations of 100, 10, 1, 0.1 and 0.01 μM. At the end of incubation, 20 μl of alamarBlue 90% reagent was added to each well for another 6-hour incubation before detection of cell viability by fluorescent intensity. Fluorescent intensity was measured using a Spectraflour Plus plate reader with excitation at 530 nm and emission at 590 nm.

(2) Determination of IC₅₀, TGI and LC₅₀

The measured results was calculated by the following formula: PG (%)=100×(Mean F _(test)−Mean F _(time0))/(Mean F _(ctrl)−Mean F _(time0))] If (Mean F _(test)−Mean F _(time0))<0, then PG (%)=100×(Mean F _(test)−Mean F _(time0))/(Mean F _(time0)−Mean F _(blank)) wherein PG represents percent growth;

Mean F_(time0)=The average of 2 measured fluorescent intensities of reduced alamarBlue at the time just before exposure of cells to the test substance;

Mean F_(test)=The average of 2 measured fluorescent intensities of alamarBlue after 72-hour exposure of cells to the test substance;

Mean F_(ctrl)=The average of 2 measured fluorescent intensities of alamarBlue after 72-hour incubation without the test substance;

Mean F_(blank)=The average of 2 measured fluorescent intensities of alamarBlue in medium without cells after 72-hour incubation.

A decrease of 50% or more (≧50%) in fluorescent intensity relative to the vehicle-treated control indicates significant cytostatic or cytotoxic activity, and semi-quantitative values for IC₅₀, TGI and LC₅₀ were then determined by nonlinear regression using GraphPad Prism (GraphPad Software, USA).

IC₅₀ (50% Inhibition Concentration); Test compound concentration where the increase from times in the number or mass of treated cells was only 50% as much as the corresponding increase in the vehicle-control at the end of experiment.

TGI (Total Growth Inhibition): Test compound concentration where the number or mass of treated cells at the end of experiment was equal to that at time₀.

LC₅₀ (50% Lethal Concentration): Test compound concentration where the number or mass of treated cells at the end of experiment was half that at time.

Cytotoxicity Assays Method B (HL-60) [H. M. Chen et al. Chin. Pharm. J. 53, 157-167 (2001)]

Cells and Culture

Human promyeloid leukemia HL-60 cells were obtained from the American Type

Culture Collection (Manassas, Va., USA) and the Culture Collection and Research Center(CCRC) (Tai wan, ROC). Human promyeloid leukemia HL-60 cells were cultured in suspension in RPMI-1640 medium (GIBCO, Grand Is land, USA), containing 10% fetal bovine se rum (GIBCO, Grand Is land, USA), 100 unit/mL penicillin, 100 mL/mL streptomycin and 1% L-glutamine at 37° C. in a humidified atmosphere of 5% CO2 in air. Cells were split every day to maintain the cell numbers between 2−5×10⁵/mL. Cell numbers were assessed by the standard procedure of leukocyte counting using a hemocytometer and cell viability was checked by the ability of cells to exclude Trypan blue.

MTT Proliferation Assay

Cellular proliferation was determined by the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] as say. Briefly, 10 mL of MTT (5 mg/mL) was added to each well of 96-well plates containing 1×10⁵ cells after treatment with different concentrations of samples for 4 days. The reaction was stopped after 2 h by adding 100 mL of 0.04 N HCl in isopropanol and the OD570 nm was determined by a minicolorimetric reader. Each concentration treatment was performed in triplicate.

Cytotoxicity Assays Method C (KB, KB-VIN, AS49, HCT-8, PC-3) [K. H. Lee et. al. Planta Med. 54, 308-312 (1998), Monk A et. al. J. Natl. Cancer Inst. 83, 757-766 (1991).] The cell lines included epidermoid caninoma of the nasopharynx (KB), p-gp-expressing epidermoid caninoma of the nasopharynx (KB-VIN), lung carcinoma (A-549), ileocecal carinoma (HCT-8) and prostate cancer (PC-3) cell lines. The cytotoxic effects of each compounds were obtained as IC₅₀ in microgram per ml, the concentration that give 50% inhibition of cell growth after 72 hrs of continuous exposure-variation was less than 5% between replicates.

Anticancer Activity

The assays were used to detect changes in cell proliferation based on the ability of viable cells to cause alamarBlue to change from its oxidized to a reduced form. With the results obtained from the alamarBlue reaction, cell proliferation can be quantified and metabolic activity of viable cell can be examined.

The succinate derivatives of compounds IIa-1, IIb-1 and VII-1 were tested for possible effect on the proliferation of four human tumor cell lines ˜MCF-7 (breast), HT-29 (colon), Hep3B (liver), and NCl—H 460 (lung) as well as one human umbilical vein endothelial cell (HUVEC) at assay concentration from 0.01 to 100 μM, through serial 10-fold dilution.

The IC₅₀ (50% inhibition concentration), TGI (total growth inhibition) and LC₅₀ (50% lethal concentration) of the three tested compounds were summary in Table 1.

As shown in Table 1, the three tested compounds showed potent cytotoxicity in vitro against NCl—H 460 cell line. Compounds IIa-1 and IIb-1 also had significant activity against MCF-7 and Hep3B cell lines. These two compounds displayed moderate and little activity against HT-29 cell line. Compound VII-1 showed significant cytotoxicity against MCF-7 and Hep3B and moderate activity against HT-29 cell line. On the other hand, all the three tested compounds were essentially inactive or showed little activity in HUVEC assay.

Compound IIa-1-IIa-2-IIb-1-IIb-2-VII-1-VII-2-IX and XV-2-H₃PO₄ were evaluated for their cytotoxicity in vitro against human promyelocytic leukemia (HL-60) cell line. As shown in Table 2. All of these tested compounds showed significant cytotoxicity. Among them, XV-2-H₃PO₄ was the most potent one. There fore this compound was selected for further evaluation.

Mono-[1-(4,8dioxo-4,8-dihydrobenzo[1,2-b:5,4-b′]dithiophen-2-yl)-methyl]succinate (IIa-1), mono-[1-(4,8-dioxo-4,8-dihydrobenzo[1,2-b:5,4-b′]dithiophen-2-yl)-methyl]pentanedioate (IIa-2), mono-[1-(4,8-dioxo-4,8-dihydrobenzo[1,2-b:5,4-b′]dithiophen-2-yl)-ethyl]succinate (IIb-1), mono-[1-(4,8dioxo-4,8-dihydrobenzo[1,2-b:5,4-b′]dithiophen-2-yl)-ethyl]pentanedioate (IIb-2), ethyl 4,8-dioxo-4,8-dihydroxybenzo[1,2-b:5,4-b′]-dithiophen-2-yl-methoxy acetate (IVa), mono-[1-(4,8-dioxo-4,8-dihydroxybenzo[1,2-b;4,5-b′]dithiophen-2-yl)-ethyl]succinate (VII-1), mono-[1-(4,8-dioxo-4,8-dihydroxybenzo[1,2-b;4,5-b′]dithiophen-2-yl)-ethyl]pentanedioate (VII-2), 1-(4,8-Dioxo-4,8-dihydroxybenzo[1,2-b:4,5-b′]-dithiophen-2-yl-ethoxy)-acetate (IX), 4,8-dioxo-4,8-dihydrobenzo-[1,2-b;5,4-b′]dithiophene-2-carboxylic acid (XI), 4,8-dioxo-4,8-dihydrobenzo-[1,2-b;4,5-b′]dithiophene-2-carboxylic acid (XIV), 4,8-dioxo-4,8-dihydrobenzo-[1,2-b;4,5-b′]dithiophene-2-carboxylate-(2-dimethylamino-ethyl)-amide phosphate (XV-2-H₃PO₄), (L)-2-{(4,8-Dioxo-4,8-dihydrobenzo-[1,2-b;4,5-b′]dithiophene-2-carbonyl)-amino}-propionic acid (XVI), and their salts were evaluated for their cytotoxicity in vitro against epidermal carcinoma of the nasopharynx (KB), p-gp-expressing epidermoid carcinoma of the nasopharynx (KB-VIN), lung carcinoma (A-549), ileocecal carcinoma (HCT-8) and prostate cancer (PC-3). As shown in Table 2, Most of these tested compounds showed significant cytotxicity. Among them, XV-2-H₃PO₄ was the most promising agent. In addition, compounds IIb-1, IIb-2, VII-1and VII-2 displayed potent activity against the MDR cell line (KB-VIN) and the androgen-insensitive prostate cancer cell line (PC-3). Therefore, compounds XV-2-H₃PO₄, IIb-1, IIb-2 VII-1 and VII-2 were selected for further pharmacological studies. In summary, the present invention demonstrated remarkable therapeutical potential for benzodithiophenone analogs in the treatment of cancers.

The present invention also discloses a hydrophilic compound having the following structures (F) or (G), or a pharmaceutically acceptable salt thereof:

wherein A₃ and A₄ independently are —U—C(O)—(CH₂)_(n)COOH, —U—(CH₂)_(n)—COOH, —U(CH₂)_(n)—NR₅R₆,

wherein U is O, S, or NH, R₅ is H or alkyl; R₆ is H or alkyl; and n is 1-5; and Y, Z, R₁, R₂, R₃ and R₄ are defined as above.

The present invention also discloses a method for treating a tumor, said method comprising administering to a subject in need of treatment a compound having the formulas (F) or (G) as defined above, or a pharmaceutically acceptable salt thereof, in an amount effective to treat said tumor. TABLE 1 Cytotoxicity of compounds IIa-1, IIb-1, and VII-1 against MCF7, HT-29, Hep-3B, NCI-H460 and HUVEC cell lines

HUVEC MCF-7 HT-29 Hep-3B HCI-H460 Compounds IC₅₀ ^(a) TGI^(b) LC₅₀ ^(c) IC₅₀ ^(a) TGI^(b) LC₅₀ ^(c) IC₅₀ ^(a) TGI^(b) LC₅₀ ^(c) IC₅₀ ^(a) TGI^(b) LC₅₀ ^(c) IC₅₀ ^(a) TGI^(b) LC₅₀ ^(c) IIa-1 10 19 34 3.4 6.9 14 11 22 45 2.8 5.1 9.2 0.81 1.7 3.5 IIb-1 11 31 89 0.82 4.7 27 4.3 2.0 89 1.1 1.8 2.9 0.64 1.2 2.1 VII-1 11 57 >100 0.96 5.5 31 4.5 38 >100 1.0 1.9 3.4 0.41 1.1 3.0 ^(a)IC₅₀ (50% Inhibition Concentration): Test compound concentration μM where the increase from time₀ in the number or mass of treated cells was only 50% as much as the corresponding increase in the vehicle-control at the end of experiment. ^(b)TGI (Total growth Inhibition): Test compound concentration μM where the number or mass of treated cells at the end of experiment was equal to that at time₀. ^(c)LC₅₀ (50% Lethal Concentration): Test compound concentration μM where the number or mass of treated cells at the end of experiment was half that at time₀.

TABLE 2 Cytotoxicity of compounds IIa-1, IIa-2, IIb-1, IIb-2, VII-1, VII-2, IX and XV-2-H₃PO₄ against HL-60 cell line^(a).

Compound R IC₅₀ (uM)^(b) IIb-1 —CH(CH₃)—OCO(CH₂)₂COOH 0.26 IIb-2 —CH(CH₃)—OCO(CH₂)₃COOH 0.25 IIa-1 —CH₂—OCO(CH₂)₂COOH 0.47 IIa-2 —CH₂—OCO(CH₂)₃COOH 0.70 VII-1 —CH(CH₃)—OCO(CH₂)₂COOH 0.26 VII-2 —CH₂—OCO(CH₂)₃COOH 0.28 XVI —CONHCH(CH₃)COOH 0.75 IX —CH(CH₃)OCH₂COOH 2.58 XV-2-H₃PO₄ —CONH(CH₂)₂N(CH₃)₂H₃PO₄ 0.05 ^(a)Human promyielocytic leukemia (HL-60). ^(b)IC₅₀ values are the concentration at which 50% of the cells are inhibited from growing.

TABLE 3 Cytotoxicity of compounds IIa-1, IIa-2, IIb-1, IIb-2, IVa, VII-1, VII-2, IX, XI, IV, XV, XVI and their salts against KB, KB-VIN, A-549, HCF-8 and PC-3 cell lines.

IC₅₀ (uM)^(a) Compound R KB^(b) KB-VIN^(c) A549^(d) HCT-8^(c) PC-3^(f) IIb-1 —CH(CH₃)—O—CO—(CH₂)₂COOH 0.47 0.25 0.58 0.91 0.22 IIb-1-Na —CH(CH₃)—O—CO—(CH₂)₂COONa 0.55 0.47 0.47 1.83 0.37 IIb-2 —CH(CH₃)—O—CO—(CH₂)₃COOH 0.03 0.05 0.11 0.19 0.06 IIb-2-Na —CH(CH₃)—O—CO—(CH₂)₃COONa 1.36 1.13 1.89 1.89 0.88 IIa-1 —CH₂—O—CO—(CH₂)₂COOH 2.02 4.47 4.03 4.03 1.35 IIa-1-Na —CH₂—O—CO—(CH₂)₂COONa 2.09 3.79 3.79 3.25 1.22 IIa-2 —CH₂—O—CO—(CH₂)₃COOH 2.22 1.39 2.08 1.66 0.75 IIa-2-Na —CH₂—O—CO—(CH₂)₃COONa 1.72 1.31 0.94 0.65 0.89 IVa —CH₂—O—CH₂COOH 3.61 2.46 2.46 2.07 1.05 XI —COOH 38.31 38.31 30.27 37.16 13.41 XI-NH₄ —COONH₄ 35.97 35.97 >70 >70 >70 VII-1 —CH(CH₃)—OCO—(CH₂)₂COOH 0.19 0.22 0.47 0.42 0.16 VII-1-Na —CH(CH₃)—OCO—(CH₂)₂COONa 2.14 1.96 2.22 1.44 0.73 VII-2 —CH(CH₃)—OCO—(CH₂)₃COOH 0.08 0.24 0.51 0.48 0.06 VII-2-Na —CH(CH₃)—OCO—(CH₂)₃COONa 0.45 0.68 2.52 0.88 0.10 XIV —COOH 38.31 38.31 44.44 44.06 25.29 XIV-NH₄ —COONH₄ 35.97 35.97 16.19 26.26 13.31 XV-2-H₃PO₄ —CONH(CH₂)₂—N(CH₃)₂—H₃PO₄ 0.06 0.01 0.01 0.01 0.01 XVI-Na —CONH—C(CH₃)COONa 1.76 0.54 0.54 0.51 0.17 IX —CH(CH₃)—O—CH₂COOH 19.75 18.18 2.60 0.24 2.51 IX-Na —CH(CH₃)—O—CH₂COONa 1.11 1.00 0.26 0.22 0.14 Doxorubincin 0.18 4.97 0.18 ND^(g) ND^(g) VP-16 4.76 >10 1.36 ND^(g) ND^(g) VCR 0.01 5.33 0.04 ND^(g) ND^(g) ^(a)IC₅₀ was the concentration of compound which afforded 50% reduction in cell number after 72 hr of incubation. ^(b)epidermoid carcinoma of the nasopharynx (KB). ^(c)p-gp-expressing epidermoid carcinoma of the nasopharynx (KB-VIN). ^(d)lung carcinoma (A-549). ^(e)ileocecal carcinoma (HCT-8). ^(f)prostate cancer (PC-3). ^(g)ND = Not active at 20 mcq/mL.

The water solubility of some of the synthesized compounds were tested and summarized as below. Compound Solubility

9.6 × 10⁻³ mg/1 mL H₂O 1b

≧3 mg/1 mL H₂O IIb-1-Na

≧9.6 mg/1 mL H₂O IIb-2-Na

≧10 mg/1 mL H₂O XI-NH₄

≧10 mg/1 mL H₂O XI-Na

≧2 mg/1 mL H₂O XVII-H₃PO₄

≧6.6 mg/1 mL H₂O XIII-Na

≧3.2 mg/1 mL H₂O IVb-Na

≧10 mg/1 mL H₂O IIa-1-Na

≧1.8 mg/1 mL H₂O IIa-2-Na

≧9.6 mg/1 mL H₂O IVa-Na

≧10 mg/1 mL H₂O VII-1-Na

≧3.4 mg/1 mL H₂O VII-2-Na

−4 mg/1 mL H₂O XIV-NH₄

≧4 mg/1 mL H₂O XV-2-H₃PO₄

≧3.2 mg/1 mL H₂O XVI-Na

≧6 mg/1 mL H₂O IX-Na 

1. A derivative of 4,8-dihydrobenzodithiophene-4,8-dione having the formulas (D) or (E):

wherein Y and Z independently are O, S, —NH—, or Se; A₁ and A₂ independently are O, S, or NR₅, wherein R₅ is H or alkyl; R₁, R₂, R₃ and R₄ independently are H, alkyl, —CR₅R₆—X—C(O)—(CH₂)_(n)COOH, —CR₅R₆—X—(CH₂)_(n)COOH, —CR₅R₆—X—(CH₂)_(n)NR₅R₆, —C(O)—NR₆—(CR₅R₆)_(n)COOH, —C(O)—NR₆—(CR₅R₆)_(n)NR₅R₆, —CR₅R₆—C(O)—(CH₂)_(n)COOH, —CR₅R₆—X—C(O)—(CH₂)_(n)NR₅R₆, —C(O)—(CR₅R₆)_(n)COOH, —C(O)—(CR₅R₆)_(n)NR₅R₆, —CR₅═N—(CH₂)_(n)COOH, —CR₅═N—(CH₂)_(n)NR₅R₆, —CR₅═NOH, or

wherein X is O, S, or NH; R₅ is defined as above; R₆ is H or alkyl; and n is 1-5; subject to the proviso that at least one of R₁, R₂, R₃ and R₄ is a radical other than hydrogen and alkyl; or a pharmaceutically acceptable salt thereof.
 2. The derivative as defined in claim 1, wherein R₂, R₃ and R₄ are H, and R₁ is —CR₅R₆—X—C(O)—(CH₂)_(n)COOH, —CR₅R₆—X—(CH₂)_(n)COOH, —CR₅R₆—X—(CH₂)_(n)NR₅R₆, —C(O)—NR₆(CR₅R₆)_(n)COOH, or —C(O)—NR₆—(CR₅R₆)_(n)NR₅R₆, wherein X, R₅, R₆ and n are defined as in claim
 1. 3. The derivative as defined in claim 1, wherein Y and Z are S.
 4. The derivative as defined in claim 2, wherein Y and Z are S.
 5. The derivative as defined in claim 1, wherein A₁ and A₂ are O.
 6. The derivative as defined in claim 2, wherein A₁ and A₂ are O.
 7. The derivative as defined in claim 3, wherein A₁ and A₂ are O.
 8. The derivative as defined in claim 4, wherein A₁ and A₂ are O.
 9. The derivative as defined in claim 8, wherein X is O.
 10. The derivative as defined in claim 9, wherein R₅ and R₆ independently are H or methyl.
 11. The derivative as defined in claim 10, wherein R₁ is —CR₅R₆—X—C(O)—(CH₂)_(n)COOH.
 12. The derivative as defined in claim 10, wherein R₁ is —CR₅R₆—X—(CH₂)_(n)COOH.
 13. The derivative as defined in claim 10, wherein R₁ is —CR₅R₆—X—(CH₂)_(n)NR₅R₆.
 14. The derivative as defined in claim 10, wherein R₁ is —C(O)—NR₆—(CR₅R₆)_(n)COOH.
 15. The derivative as defined in claim 10, wherein R₁ is —C(O)—NR₆—(CR₅R₆)_(n)NR₅R₆.
 16. The derivative as defined in claim 10 having the formula (D).
 17. The derivative as defined in claim 10 having the formula (E).
 18. The derivative as defined in claim 10, which is mono-[1-(4,8-dioxo-4,8-dihydrobenzo[1,2-b:5,4-b′]dithiophen-2-yl)-methyl]succinate (IIa-1), mono-[1-(4,8-dioxo-4,8-dihydrobenzo[1,2-b:5,4-b′]dithiophen-2-yl)-ethyl]succinate (IIb-1), or mono-[1-(4,8-dioxo-4,8-dihydrobenzo[1,2-b:5,4-b′]dithiophen-2-yl)-ethyl]pentanedioate (IIb-2); mono-[1-(4,8-dioxo-4,8-dihydroxybenzo[1,2-b;4,5-b′]dithiophen-2-yl)-ethyl]succinate (VII-1), mono-[1-(4,8-dioxo-4,8-dihydroxybenzo[1,2-b;4,5-b′]dithiophen-2-yl)-ethyl]pentanedioate (VII-2), or 4,8-dioxo-4,8-dihydrobenzo[1,2-b;4,5-b′]dithiophene-2-carboxylate-(2-dimethylamino-ethyl)-amide (XV-2).
 19. A method for treating a tumor, said method comprising administering to a subject in need of treatment a derivative of 4,8-dihydrobenzodithiophene-4,8-dione having the formulas (D) or (E) as defined in claim 1, or a pharmaceutically acceptable salt thereof, in an amount effective to treat said tumor.
 20. The method as defined in claim 19, wherein said tumor is selected from the group consisting of non-small cell lung cancer, breast cancer, nasopharynx carcinoma, prostate cancer, colon cancer, hepatoma, ileocecal carcinoma, leukemia and central nervous system cancers.
 21. The method as defined in claim 20, wherein said tumor is selected from the group consisting of non-small cell lung cancer, breast cancer, nasopharynx carcinoma and prostate cancer.
 22. The method as defined in claim 20, wherein R₂, R₃ and R₄ are H, and R₁ is —CR₅R₆—X—C(O)—(CH₂)_(n)COOH, —CR₅R₆—X—(CH₂)_(n)COOH, —CR₅R₆—X—(CH₂)_(n)NR₅R₆, —C(O)—NR₆—(CR₅R₆)_(n)COOH, or —C(O)NR₆—(CR₅R₆)_(n)NR₅R₆, wherein X, R₅, R₆ and n are defined as in claim
 1. 23. The method as defined in claim 20, wherein Y and Z are S.
 24. The method as defined in claim 22, wherein Y and Z are S.
 25. The method as defined in claim 20, wherein A₁ and A₂ are O.
 26. The method as defined in claim 22, wherein A₁ and A₂ are O.
 27. The method as defined in claim 23, wherein A₁ and A₂ are O.
 28. The method as defined in claim 24, wherein A₁ and A₂ are O.
 29. The method as defined in claim 28, wherein X is O.
 30. The method as defined in claim 29, wherein R₅ and R₆ independently are H or methyl.
 31. The method as defined in claim 30, wherein R₁ is —CR₅R₆—X—C(O)—(CH₂)_(n)COOH.
 32. The method as defined in claim 30, wherein R₁ is —CR₅R₆—X—(CH₂)_(n)COOH.
 33. The method as defined in claim 30, wherein R₁ is —CR₅R₆—X—(CH₂)_(n)NR₅R₆.
 34. The method as defined in claim 30, wherein R₁ is —C(O)—NR₆—(CR₅R₆)_(n)COOH.
 35. The method as defined in claim 30, wherein R₁ is —C(O)—NR₆—(CR₅R6)_(n)NR₅R₆.
 36. The method as defined in claim 30 having the formula (D).
 37. The method as defined in claim 30 having the formula (E).
 38. The method as defined in claim 30, which is mono-[1-(4,8-dioxo-4,8-dihydrobenzo[1,2-b:5,4-b′]dithiophen-2-yl)-methyl]succinate (IIa-1), mono-[1-(4,8-dioxo-4,8-dihydrobenzo[1,2-b:5,4-b′]dithiophen-2-yl)-ethyl]succinate (IIb-1), or mono-[1-(4,8-dioxo-4,8-dihydrobenzo[1,2-b:5,4-b′]dithiophen-2-yl)-ethyl]pentanedioate (IIb-2); mono-[1-(4,8-dioxo-4,8-dihydroxybenzo[1,2-b;4,5-b′]dithiophen-2-yl)-ethyl]succinate (VII-1), mono-[1-(4,8-dioxo-4,8-dihydroxybenzo[1,2-b;4,5-b′]dithiophen-2-yl)-ethyl]pentanedioate (VII-2), or 4,8-dioxo-4,8-dihydrobenzo[1,2-b;4,5-b′]dithiophene-2-carboxylate-(2-dimethylamino-ethyl)-amide (XV-2).
 39. A compound having the following structures (F) or (G):

wherein A₃ and A₄ independently are —U—C(O)—(CH₂)_(n)COOH, —U—(CH₂)_(n)—COOH, —U(CH₂)_(n)—NR₅R₆,

wherein U is O, S, or NH, R₅ is H or alkyl; R₆ is H or alkyl; and n is 1-5; and Y, Z, R₁, R₂, R₃ and R₄ are defined as in claim 1, or a pharmaceutically acceptable salt thereof.
 40. A method for treating a tumor, said method comprising administering to a subject in need of treatment a compound having the formulas (F) or (G) as defined in claim 39, or a pharmaceutically acceptable salt thereof, in an amount effective to treat said tumor. 